Press Releases
Media Library
Social Media
Analyst Coverage
Annual and Interim Reports
Annual General Meeting
Annual Report 2016
Conflict Minerals Disclosure
Debt Investors
Dividend
Email Alerts
Events
Financial Highlights
Investor News
Our Strategy
Quarterly Results and Presentations
Recent Acquisitions
Shareholder Information
Stock Information
WHO WE ARE
Our Story
Rare Champions
Responsibility
Leadership
How We Operate
PATIENTS
Patient Services
Patient Advocacy
Therapeutic Areas
Humanitarian Access
Scholarships
R&D
Our R&D Strategy
RESEARCH AND EDUCATIONAL GRANTS
Science & Innovation
Clinical Trials
Pipeline
Collaborations
PRODUCTS
Product List
Manufacturing
Postmarketing Commitments
CAREERS
Search & Apply
Diversity & Inclusion
Culture & Values
Growing Your Career
Benefits
US Internship Program
Work Life Balance
Employee Profiles
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
Shire to announce second quarter 2017 results
Shire Obtains Injunction Against Roche to Address Incomplete and Misleading Statements Regarding Investigational Agent Emicizumab That May Impact Patient Safety
Additional Listing
Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A
Director/PDMR Shareholding
Total Voting Rights
Shire to present new data at ISTH 2017 to advance the standard of care in Hemophilia
Shire announces EMA validation of VEYVONDI™ [von Willebrand factor (Recombinant)] Marketing Authorization Application for treatment of von Willebrand disease
Director Declaration
U.S. FDA Approves Mydayis™ (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older
Shire to participate at the Jefferies healthcare conference
Block listing six monthly return
Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology
Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
The Lancet Publishes Phase 2 Results from Shire’s Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis
Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association
Shire delivers strong Q1 2017 revenue growth while advancing late-stage pipeline
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Shire opens new HQ office in Dublin City Centre
Shire Granted EU Conditional Marketing Authorisation for Natpar®▼ (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism
LOAD MORE
Learn more
We make decisions that put patients first.
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.